000766 · SZSE · China
thjm.cnFinancials as of FY2025
Manufactures both traditional Chinese herbal medicines and conventional pharmaceuticals inside one government-licensed facility, keeping its drugs embedded in China's hospital system.
What this company is and how it runs — written from structure, not news.
Tonghua Golden-Horse Pharmaceutical holds a single NMPA facility licence covering two physically separate manufacturing lines — one for traditional Chinese medicine botanical preparations and one for conventional pharmaceuticals — and that combination is what gets its products written into China's provincial hospital formularies as a matched pair from one supplier. Because the two lines share one facility registration, a GMP inspection failure on either side suspends both simultaneously, so the entire revenue base rests on keeping two independent compliance regimes clean at once. The TCM extraction equipment cannot be repurposed for conventional batches, and vice versa, so when provincial bidding shifts demand toward one category the other line simply runs light — there is no mechanical way to rebalance output. A competitor wanting to replicate this would need to run both lines through separate multi-year NMPA certification cycles concurrently and then win formulary placement product by product before seeing any hospital revenue, which is why the dual-line licence, once held, is effectively irreplaceable.
How does this company make money?
Most revenue comes from selling drugs to hospitals at prices set through provincial government bidding rounds, where the company wins a contracted price for a fixed period and then fulfills orders at that rate. It also sells traditional medicine products through pharmacies at manufacturer-suggested retail prices, with distributors taking a margin along the way. A smaller share comes from export sales, where prices are negotiated directly with international buyers on a contract-by-contract basis.
What makes this company hard to replace?
Hospital procurement contracts run for multiple years and name specific drug formulations, so replacing a product mid-contract is not a simple purchasing decision. Doctors who prescribe traditional Chinese medicine products build familiarity with particular preparations, specific dosing conventions, and administration methods that do not transfer automatically to a substitute product. Any competitor trying to take a hospital's business would first need to complete the provincial formulary qualification process — years of documentation and relationship-building — before a single purchase order could change hands.
What limits this company?
The equipment used to extract and concentrate herbal botanical materials can only process herbal ingredients — it cannot be switched over to make conventional pharmaceutical batches. So when hospital purchasing shifts demand from one type of drug to the other, neither production line can absorb the other's workload. The physical and regulatory separation that keeps the licence valid is exactly what prevents the company from rebalancing output.
What does this company depend on?
The company cannot operate without NMPA drug registration certificates for each product and both lines. It relies on traditional Chinese medicine raw material suppliers to deliver the herbs and botanical extracts that feed the TCM line. It needs specialized TCM extraction and concentration equipment that is purpose-built and not interchangeable with standard pharmaceutical machinery. It also depends on China's hospital procurement system for the bulk of its sales, and on provincial drug bidding qualification approvals to remain an eligible supplier in each region.
Who depends on this company?
Chinese hospitals depend on this company for specific traditional Chinese medicine formulations written into their treatment protocols — losing access would disrupt patient care for conditions where those named formulations are prescribed. Provincial health systems that have built this company's drugs into their approved formularies would face procurement gaps and administrative disruption if supply stopped. Chinese pharmacies that stock its over-the-counter traditional medicine products would lose those lines for consumer self-medication.
How does this company scale?
Formulation knowledge and regulatory approvals can be applied across more production batches at little extra cost once they exist — making more units of an already-registered drug is relatively cheap. What does not scale easily is the specialized TCM extraction equipment and the qualified technicians who understand both traditional preparation methods and pharmaceutical GMP standards. Hiring and training more of those people, or installing more of that equipment, takes significant time and cannot be rushed.
What external forces can significantly affect this company?
China's Traditional Chinese Medicine Development Strategy actively pushes TCM into mainstream healthcare, which creates policy tailwinds but also invites more government direction over the industry. An aging Chinese population is steadily increasing demand for traditional medicine and chronic disease treatments, expanding the market. U.S.-China trade tensions create uncertainty around sourcing active pharmaceutical ingredients and limit the company's ability to grow export sales to international buyers.
Where is this company structurally vulnerable?
If NMPA inspectors find a compliance problem on either line — a miscalibrated piece of equipment, a gap in cross-contamination controls, or incomplete technician qualification records — they can suspend the single facility licence that covers both lines at once. Because both lines sit under one registration, a deficiency on the herbal side shuts down the conventional pharmaceutical side too, and vice versa. That would immediately void the provincial formulary contracts and hospital procurement agreements that the entire business is built on.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped declining and bounced upward, and (2) current price is back inside or just above that zone after a meaningful drawdown from peak. The retest is a real one — the stock is not at a new all-time high being measured as a low.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Three observations describe the present configuration: the current close sits below the 40-week SMA (the conventional 'below 200-day SMA'), the company has reported positive net income in each of the last three annual periods, and operating cash flow exceeded net income in the most recent annual period.
Three observations describe the present configuration: drawdown from the trailing peak is significant, free cash flow has been positive in each of the last three annual periods, and operating cash flow exceeded net income in the most recent annual period.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph